Showing 1261-1270 of 1414 results for "".
- Ocugen Granted FDA Orphan Drug Designation for Gene Therapy for the Treatment of RHO Mutation-Associated Retinal Degenerative Diseasehttps://modernod.com/news/ocugen-granted-fda-orphan-drug-designation-for-gene-therapy-for-the-treatment-of-rho-mutation-associated-retinal-degenerative-disease/2478081/Ocugen announced the FDA granted the third orphan drug designation (ODD) for OCU400 in the treatment of RHO mutation-associated retinal degeneration. The RHO mutation is part of the retinitis pigmentosa (RP) group of rare, genetic disorders that involve a breakdown and loss of
- MPR and MacuLogix Received A’Design Awardhttps://modernod.com/news/mpr-and-maculogix-received-adesign-award/2477781/MPR and MacuLogix were recognized with the A’Design Platinum Award, the world’s largest design competition, for its work on the AdaptDx Pro, a medical headset by MacuLogix. Launched earlier this year, the device build
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Johnson & Johnson Vision Releases Data From Study of Acuvue Oasys With Transitions Light Intelligent Technologyhttps://modernod.com/news/johnson-johnson-vision-releases-data-from-study-of-acuvue-oasys-with-transitions-light-intelligent-technology/2477034/Johnson & Johnson Vision announced new data from a study of its Acuvue Oasys with Transitions Light Intelligent Technology, which found the benefits of these first-of-its-kind light adaptive contact lens were deemed highly valued and useful by people who had never w
- Tilak Healthcare Announces Exclusive Partnership for Co-Promotion with Novartis Francehttps://modernod.com/news/tilak-healthcare-announces-exclusive-partnership-for-co-promotion-with-novartis-france/2476578/Tilak Healthcare, a video game studio specializing in mobile medical games for patients with chronic diseases, announced an exclusive co-promotion partnership with Novartis France for OdySight, its first clinically validated mobile game to monitor vision remotely. Tilak He
- Johnson & Johnson Vision Announces Availability of Acuvue Oasys With Transitions Light Intelligent Technology in the U.S.https://modernod.com/news/johnson-johnson-vision-announces-availability-of-acuvue-oasys-with-transitions-light-intelligent-technology-in-the-u-s/2479584/Johnson & Johnson Vision announced the US availability of Acuvue Oasys with Transitions Light Intelligent Technology. The contact lenses adapt to changing light, helping eyes recover from bright light up to 5 seconds faster, reducing halos and starbursts at night, and delivering more sight w
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- MacuLogix Raises $38.7 Million in Series D Financing to Support Growthhttps://modernod.com/news/maculogix-raises-38-7-million-in-series-d-financing-led-by-vivo-capital/2479587/MacuLogix has completed a Series D round of financing totaling $38.7 million to further expand the MacuLogix team and company infrastructure to support the growing sales and practice integration efforts of the AdaptDx
- MacuLogix Enters International Distribution Agreement with Optoshttps://modernod.com/news/maculogix-enters-international-distribution-agreement-with-optos/2479750/MacuLogix has entered into an international distribution agreement with Optos, part of Nikon Corporation. Effective immediately, Optos in Europe and Australia, will add the AdaptDx automated dark adaptometer to their
- MacuLogix Launches AMD Academyhttps://modernod.com/news/maculogix-launches-amd-academy/2479861/MacuLogix has launched its AMD Academy, an online learning community for current AdaptDx users, delivering video-based product training and a user forum to facilitate discussion of best practices and answers to user questions. “MacuLogix provides extensive, in-person training to eac